Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Inclusion Criteria:

- Completed week 80 of study 20120153 (NCT01813422).

Exclusion Criteria:

- Did not complete investigational product in the 20120153 parent study

- Have an unstable medical condition, in the judgment of the investigator

- Known sensitivity to any of the products to be administered during dosing

- Currently enrolled in another investigational device or drug study (excluding
evolocumab (AMG 145) parent study), or less than 30 days since ending another
investigational device or drug study(s),or receiving other investigational agent(s)